Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HOWL Werewolf Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: HOWL
Price (delayed)
$1.31
Market cap
$58.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
$3.76M
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its
Highlights
Werewolf Therapeutics's debt has decreased by 28% YoY
The quick ratio has increased by 20% year-on-year and by 8% since the previous quarter
Werewolf Therapeutics's revenue has plunged by 93% YoY and by 39% from the previous quarter
The gross profit has plunged by 93% YoY and by 39% from the previous quarter
Key stats
What are the main financial stats of HOWL
Market
Valuations
Earnings
Shares outstanding
44.87M
Market cap
$58.78M
Enterprise value
$3.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.02
Price to sales (P/S)
51.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.29
Revenue
$1.14M
Gross profit
$1.14M
Operating income
-$74.42M
Net income
-$72.41M
EBIT
-$67.5M
EBITDA
-$65.02M
Free cash flow
-$59.98M
Per share
Balance sheet
Liquidity
EPS
-$1.64
EPS diluted
-$1.65
Free cash flow per share
-$1.34
Book value per share
$1.28
Revenue per share
$0.03
TBVPS
$2.39
Total assets
$107.24M
Total liabilities
$49.93M
Debt
$37.01M
Equity
$57.31M
Working capital
$82.79M
Debt to equity
0.65
Current ratio
8.09
Quick ratio
7.89
Net debt/EBITDA
0.85
Margins
Efficiency
Dividend
EBITDA margin
-5,688.5%
Gross margin
100%
Net margin
-6,335.2%
Operating margin
-6,511.2%
Return on assets
-54.9%
Return on equity
-89.4%
Return on invested capital
-165.1%
Return on capital employed
-70.6%
Return on sales
-5,905.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOWL stock price
How has the Werewolf Therapeutics stock price performed over time
Intraday
-3.68%
1 week
7.38%
1 month
44.8%
1 year
-64.01%
YTD
-11.49%
QTD
34.75%
Financial performance
How have Werewolf Therapeutics's revenue and profit performed over time
Revenue
$1.14M
Gross profit
$1.14M
Operating income
-$74.42M
Net income
-$72.41M
Gross margin
100%
Net margin
-6,335.2%
Werewolf Therapeutics's revenue has plunged by 93% YoY and by 39% from the previous quarter
The gross profit has plunged by 93% YoY and by 39% from the previous quarter
The company's net income has shrunk by 74% YoY and by 2.7% QoQ
Werewolf Therapeutics's net margin has shrunk by 69% QoQ
Price vs fundamentals
How does HOWL's price correlate with its fundamentals
Growth
What is Werewolf Therapeutics's growth rate over time
Valuation
What is Werewolf Therapeutics stock price valuation
P/E
N/A
P/B
1.02
P/S
51.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.29
HOWL's EPS has plunged by 50% YoY
The equity has plunged by 51% YoY and by 22% from the previous quarter
HOWL's price to book (P/B) is 22% lower than its 5-year quarterly average of 1.3 but 13% higher than its last 4 quarters average of 0.9
Werewolf Therapeutics's revenue has plunged by 93% YoY and by 39% from the previous quarter
HOWL's price to sales (P/S) is 85% higher than its last 4 quarters average of 27.7
Efficiency
How efficient is Werewolf Therapeutics business performance
Werewolf Therapeutics's return on equity has shrunk by 147% YoY and by 22% QoQ
Werewolf Therapeutics's return on assets has shrunk by 136% YoY and by 17% QoQ
HOWL's ROS has plunged by 69% from the previous quarter
HOWL's ROIC is down by 20% QoQ
Dividends
What is HOWL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOWL.
Financial health
How did Werewolf Therapeutics financials performed over time
The total assets is 115% higher than the total liabilities
The total assets is down by 40% YoY and by 16% QoQ
HOWL's current ratio is up by 21% year-on-year and by 9% since the previous quarter
Werewolf Therapeutics's debt is 35% lower than its equity
The equity has plunged by 51% YoY and by 22% from the previous quarter
HOWL's debt to equity is up by 48% YoY and by 27% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.